Key insights
- Eli Lilly's stock is up following strong Q1 2026 earnings, raised full-year guidance, and positive analyst upgrades. Revenue and EPS beat estimates significantly. The Medicare GLP-1 Bridge program extension is a tailwind. Lilly dominates the GLP-1 market with 60% share, and its new drug Foundayo isn't cannibalizing existing sales. This positive news flow suggests continued strength in the healthcare sector and positive sentiment for large-cap pharma.
Investing.com -- Eli Lilly and Company stock is climbing +4.1% in morning trading today, reaching $986.32, as investors continue to digest the pharma giant’s blockbuster Q1 2026 results and respond positively to CFO Lucas Montarce’s appearance on NYSE Live to discuss the company’s latest milestone and earnings takeaways. Eli Lilly announced its Q1 2026 financial results, with CEO David A. Ricks declaring "2026 is off to a strong start," citing 56% revenue growth in the first quarter and a raise to full-year revenue guidance. Q1 2026 revenue came in at $19.8 billion, beating the average analyst estimate of $17.8 billion by nearly $2 billion, while non-GAAP EPS of $8.55 topped the $6.79 consensus by nearly 26%.
On the analyst front, multiple Wall Street firms have issued bullish price target upgrades in recent sessions that continue to support the stock. Barclays analyst Emily Field raised the firm’s price target on Eli Lilly to $1,400 from $1,350, keeping an Overweight rating on the shares. Guggenheim analyst Seamus Fernandez also raised the firm’s price target on Eli Lilly to $1,235 from $1,183, maintaining a Buy rating. Adding to the structural tailwinds, CMS announced an extension of the Medicare GLP-1 Bridge program, beginning no later than July 1, 2026, and running through December 2027, capping out-of-pocket obesity drug costs at $50 per month for seniors — a direct access unlock not yet reflected in Foundayo’s prescription numbers.
On the competitive landscape, Lilly’s position in the GLP-1 market remains dominant. In the U.S. market for this class of medicines, Lilly now holds 60% market share. Key rival Novo Nordisk, while still a formidable competitor, has seen its oral Wegovy outpace Foundayo’s early prescription ramp, though more than 20,000 people have started taking Foundayo, and more than 80% of those users are new to taking GLP-1s, meaning Foundayo is not cannibalizing sales of Lilly’s industry-leading injectable drugs, Zepbound and Mounjaro. The broader U.S. equity market is providing a largely neutral backdrop today, with the S&P 500 up just +0.15% and the NASDAQ slightly negative at -0.09%, confirming that LLY’s outperformance of +2.14% is driven overwhelmingly by company-specific catalysts.
The combination of a landmark earnings beat, a raised full-year guidance range of $82.0 billion to $85.0 billion in revenue and non-GAAP EPS guidance of $35.50 to $37.00, sustained bullish analyst coverage, and today’s CFO visibility on NYSE Live has created a compelling re-rating environment for LLY shares. The stock broke out of a short-term corrective bearish price channel and is finding support from its 50-day SMA, with analysts targeting the psychological resistance level at $1,000 as the next key milestone.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.